Cargando…

Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin’s lymphoma

Targeted radioimmunotherapy in non-Hodgkin’s B-cell lymphoma (NHL) offers an efficacious therapy and minimal toxicity compared to conventional chemotherapy. Iodine 131 tositumomab ((131)I-TST) is a murine monoclonal antibody against the CD20 cell surface protein and is directly covalently conjugated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burdick, Michael J, Macklis, Roger M
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886324/ https://www.ncbi.nlm.nih.gov/pubmed/20616910

Ejemplares similares

Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin’s lymphoma
por: Andemariam, Biree, et al.
Publicado: (2007)

(131)I–Tositumomab in lymphoma
por: Cheung, M.C., et al.
Publicado: (2009)

Long-term complete responses after (131)I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma
por: Buchegger, F, et al.
Publicado: (2006)

Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy
por: Kesavan, Murali, et al.
Publicado: (2017)

Standard Operating Procedure for In-house Preparation of (131)I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Pickford, Matthew D., et al.
Publicado: (2012)

Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Calais, Phillipe J., et al.
Publicado: (2012)

Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma
por: Bodet-Milin, Caroline, et al.
Publicado: (2013)

Radioimmunotherapy of Non-Hodgkin’s Lymphoma: From the ‘Magic Bullets’ to ‘Radioactive Magic Bullets’
por: Chamarthy, Murthy R., et al.
Publicado: (2011)

Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar
por: Sachpekidis, Christos, et al.
Publicado: (2019)

Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice
por: Lin, Ruoting, et al.
Publicado: (2021)

Development of DOTA-Rituximab to be Labeled with (90)Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
por: Johari doha, Fariba, et al.
Publicado: (2017)

Radioimmunotherapy-based conditioning regimen prior to autologous stem cell transplantation in non-Hodgkin lymphoma
por: Eskian, Mahsa, et al.
Publicado: (2018)

Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy
por: Gritti, Giuseppe, et al.
Publicado: (2018)

Correction: Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy
por: Gritt, Giuseppe, et al.
Publicado: (2018)

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma
por: Herrera, Alex F., et al.
Publicado: (2021)

Anti-CD37 radioimmunotherapy with (177)Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitro
por: Malenge, Marion M., et al.
Publicado: (2022)

Radioimmunotherapy of human hepatocellular carcinoma xenografts with 131I-labelled antiferritin antibody.
por: Saiful Alam, A. F.
Publicado: (1991)

Radioimmunotherapy study of (131)I-labeled Atezolizumab in preclinical models of colorectal cancer
por: Zhang, Linhan, et al.
Publicado: (2022)

Iodine-131 and Thyroid Function
por: Sun, Wenjie
Publicado: (2014)

Radioimmunotherapy of transplanted small cell lung cancer with 131I-labelled monoclonal antibody.
por: Yoneda, S., et al.
Publicado: (1988)

Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with (90)Y and (111)In for domestic radioimmunotherapy and radioscintigraphy of Non-Hodgkin’s Lymphoma
por: Gholipour, Nazila, et al.
Publicado: (2014)

Update on treatment of follicular non-Hodgkin’s lymphoma: focus on potential of bortezomib
por: Brander, Danielle M, et al.
Publicado: (2012)

Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies.
por: Lane, D. M., et al.
Publicado: (1994)

Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
por: Buchegger, Franz, et al.
Publicado: (2011)

Heterogeneity of intratumoral (111)In-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma
por: Hanaoka, Kohei, et al.
Publicado: (2015)

Peripheral T Cell Non-Hodgkin's Lymphoma following Treatment of Hodgkin's Lymphoma
por: Chang, Sun Hee, et al.
Publicado: (2015)

Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry
por: Biasoli, Irene, et al.
Publicado: (2023)

Fractionated (131)I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice
por: Violet, J A, et al.
Publicado: (2008)

Low dosage of 131iodine effects on chromosomes.
por: Rodrigues, Claudia Lopes, et al.
Publicado: (2003)

Iodine-131: Lack of efficacy: case report
Publicado: (2022)

An approach for conjugation of (177)Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients
por: Thakral, Parul, et al.
Publicado: (2014)

The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review
por: Ridwansyah, Hastono, et al.
Publicado: (2023)

The role of (18)F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using (131)I-rituximab as consolidation therapy
por: Choi, Joon Ho, et al.
Publicado: (2022)

Radioimmunotherapy for Pancreatic Carcinoma Using (131)I‐Labeled Monoclonal Antibody Nd2 in Xenografted Nude Mice
por: Inui, Akimasa, et al.
Publicado: (1996)

Bendamustine in the treatment of non-Hodgkin’s lymphomas
por: Hagemeister, Fredrick, et al.
Publicado: (2009)

Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Hauptrock, Beate, et al.
Publicado: (2008)

Exposure to glyphosate and risk of non-hodgkin lymphoma: an updated meta-analysis
por: Boffetta, Paolo, et al.
Publicado: (2021)

An Update on the Pathology and Molecular Features of Hodgkin Lymphoma
por: Satou, Akira, et al.
Publicado: (2022)

Invasive tracheobronchial aspergillosis developed during radioimmunotherapy for malignant lymphoma
por: Sato, Shuku, et al.
Publicado: (2018)

Evaluation of Iodine-123 and Iodine-131 SPECT activity quantification: a Monte Carlo study
por: Morphis, Michaella, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_apu4bkbq75jecm6aqm83u9g134